Banner NPRA

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Tecentriq® (atezolizumab): Risk of nephritis

Kadar pengguna: 2 / 5

bintang aktifbintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif
 


Description:

Healthcare professionals are informed of the new important identified risk of nephritis with use of Tecentriq® (atezolizumab).


Atezolizumab is indicated for the treatment of patients with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have experienced disease progression on approved therapy for these aberrations prior to receiving atezolizumab.

It is recommended that atezolizumab be withheld for moderate (Grade 2) immune-related nephritis, and permanently discontinued for severe nephritis (Grade 3 and 4). Patients should be referred to a renal specialist, considering renal biopsy and supportive measures as indicated. Corticosteroids and/or additional immunosuppressive agents should be administered as clinically indicated.


A Direct Healthcare Professional Communication (DHPC) letter has been issued by Roche (M) Sdn. Bhd. in agreement with NPRA to highlight this safety issue. Please refer to this DHPC for further information.

 

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Jumaat 01 November 2024, 09:13:24.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Search

Menu Utama